Last updated: 2026-09-06 03:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Acumen Pharmaceuticals, Inc. (ABOS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.19, with a market capitalization of $224.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.21 to $3.60. This page covers its latest market performance, valuation, price trends and company information.
$224.18M | |
$3.07 | |
$26.98 | |
$0.86 | |
$3.09 | |
295.80K | |
-- | |
-- | |
$3.60 | |
$1.21 | |
-- | |
-- |
Acumen Pharmaceuticals, Inc. (ABOS) last closed at $3.09 as of 2026-09-05 00:00:00, unchanged from the previous close of $3.09.
During the latest regular trading session, ABOS traded between $0.86 and $26.98, with a volume of 295.80K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Acumen Pharmaceuticals, Inc. (ABOS) moved from $2.90 to $3.19, representing a gain of 9.86% ($0.29).
The stock traded between $2.99 and $3.23 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 289.53 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.7%
ABOS is currently trading at $3.19, placing it 82.7% of the way from its 52-week low of $1.21 to its 52-week high of $3.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 61 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acumen Pharmaceuticals, Inc. (ABOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.